Industry-Sponsored Scientific Exchange

Leveraging a Novel Protein Vaccine to Widen Reach and Close the Vaccination Gap

Jörg Schelling MD; Catherine Cosgrove MBBS MRCP PhD DipHIV


September 29, 2023

COVID-19 remains an ongoing and unprecedented public health challenge, affecting millions of people worldwide and placing huge demands on healthcare systems. Join us for a promotional webinar providing an updated understanding of the COVID-19 landscape. It covers current global trends, contextualizes vaccines used early in the pandemic, and introduces Novavax’s recombinant protein vaccine. Our expert panel speaks to the vaccine’s attributes, highlighting key differentiating factors including efficacy and immunogenicity data, within the current prevention paradigm. Drawing on experiences from the previous winter season, this educational activity is an excellent opportunity to acquire knowledge and insights for the continuing efforts to advise, prevent, and protect in autumn/winter 2023.

This was a promotional event initiated, organised and funded by Novavax.  

The Nuvaxovid™ ▼ COVID-19 Vaccine (recombinant, adjuvanted)—also known as NVX-CoV2373—has been granted conditional marketing authorisation in the European Union for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.  The vaccine should be used in accordance with official recommendations.  

Please refer to your local product insert for more information.

Global information for healthcare professionals is available at:

Suspected Adverse Events should be reported via the national reporting system which can be accessed at:

COM-AU-NVD-2300002 | September 2023